Rheumatoid arthritis: What is refractory disease and how to manage it?

Autoimmunity Reviews

Volumn 10, Issue 11, 2011, Pages 707-713

  Polido Pereira, Joaquim ^a   Vieira Sousa, Elsa ^a   Fonseca, João Eurico ^a,b  

^a UNIVERSITY OF LISBON   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Refractory disease; Remission; Rheumatoid arthritis; Treatment strategies

Indexed keywords

ABATACEPT; ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLD; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; OCRELIZUMAB; OFATUMUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; VELTUZUMAB;

DISEASE ACTIVITY; DISEASE ACTIVITY SCORE 28; DISEASE CLASSIFICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PATIENT MONITORING; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SCORING SYSTEM; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; HUMANS; MONITORING, PHYSIOLOGIC; PROGNOSIS; RECURRENCE; RISK;

EID: 80052260418     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.04.023     Document Type: Review

References (97)

1. Scott D.L., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet 2010, 376:1094-1108.
2. Cush J.J. Early rheumatoid arthritis - is there a window of opportunity?. J Rheumatol Suppl 2007, 80:1-7.
3. Emery P. The Roche Rheumatology Prize Lecture. The optimal management of early rheumatoid disease: the key to preventing disability. Br J Rheumatol 1994, 33:765-768.
4. Raza K., Falciani F., Curnow S.J., Ross E.J., Lee C.Y., Akbar A.N., et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005, 7:R784-R795.
5. Moura R.A., Weinmann P., Pereira P.A., Caetano-Lopes J., Canhao H., Sousa E., et al. Alterations on peripheral blood B-cell subpopulations in very early arthritis patients. Rheumatology (Oxford) 2010, 49:1082-1092.
6. Weinmann P., Moura R.A., Caetano-Lopes J.R., Pereira P.A., Canhao H., Queiroz M.V., et al. Delayed neutrophil apoptosis in very early rheumatoid arthritis patients is abrogated by methotrexate therapy. Clin Exp Rheumatol 2007, 25:885-887.
7. Cascao R., Moura R.A., Perpetuo I., Canhao H., Vieira-Sousa E., Mourao A.F., et al. Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Res Ther 2010, 12:R196.
8. Moura R.A., Cascao R., Perpetuo I., Canhao H., Vieira-Sousa E., Mourao A.F., et al. Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. Rheumatology (Oxford) 2011, 50:278-282.
9. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
10. Banal F., Dougados M., Combescure C., Gossec L. Sensitivity and specificity of the American College of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: a systematic literature review and meta-analysis. Ann Rheum Dis 2009, 68:1184-1191.
11. Banal F.G.L., Dougados M. Ability of American College of Rheumatology 1987 Criteria to predict Rheumatoid Arthritis: a systematic literature review. Ann Rheum Dis Abstr July 2007, 66(supplement II):320.
12. Wiles N., Symmons D.P., Harrison B., Barrett E., Barrett J.H., Scott D.G., et al. Estimating the incidence of rheumatoid arthritis: trying to hit a moving target?. Arthritis Rheum 1999, 42:1339-1346.
13. van Dongen H., van Aken J., Lard L.R., Visser K., Ronday H.K., Hulsmans H.M., et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007, 56:1424-1432.
14. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
15. Grigor C., Capell H., Stirling A., McMahon A.D., Lock P., Vallance R., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004, 364:263-269.
16. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., van Zeben D., Kerstens P.J., Hazes J.M., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005, 52:3381-3390.
17. Prevoo M.L., van't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
18. van der Heijde D.M., van't Hof M., van Riel P.L., van de Putte L.B. Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J Rheumatol 1993, 20:538-541.
19. Felson D.T., Anderson J.J., Boers M., Bombardier C., Furst D., Goldsmith C., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735.
20. Wells G., Becker J.C., Teng J., Dougados M., Schiff M., Smolen J., et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009, 68:954-960.
21. Silva I., Mateus M., Branco J.C. Assessment of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) on Rheumatoid Arthritis activity prediction. Acta Reumatol Port 2010, 35:456-462.
22. Hensor E.M., Emery P., Bingham S.J., Conaghan P.G. Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS-28(CRP): can they be reduced?. Rheumatology (Oxford) 2010, 49:1521-1529.
23. Aletaha D., Ward M.M., Machold K.P., Nell V.P., Stamm T., Smolen J.S. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005, 52:2625-2636.
24. Felson D.T., Smolen J.S., Wells G., Zhang B., van Tuyl L.H., Funovits J., et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011, 63:573-586.
25. van Gestel A.M., Prevoo M.L., van't Hof M.A., van Rijswijk M.H., van de Putte L.B., van Riel P.L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996, 39:34-40.
26. Smolen J.S., Aletaha D., Bijlsma J.W., Breedveld F.C., Boumpas D., Burmester G., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637.
27. Vastesaeger N., Xu S., Aletaha D., St Clair E.W., Smolen J.S. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 2009, 48:1114-1121.
28. Smolen J.S., Landewe R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
29. Lard L.R., Visser H., Speyer I., vander Horst-Bruinsma I.E., Zwinderman A.H., Breedveld F.C., et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001, 111:446-451.
30. Nell V.P., Machold K.P., Eberl G., Stamm T.A., Uffmann M., Smolen J.S. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004, 43:906-914.
31. Lindqvist E., Jonsson K., Saxne T., Eberhardt K. Course of radiographic damage over 10years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 2003, 62:611-616.
32. van der Heijde D.M. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995, 34(Suppl. 2):74-78.
33. Knevel R., Schoels M., Huizinga T.W., Aletaha D., Burmester G.R., Combe B., et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010, 69:987-994.
34. Fransen J., Moens H.B., Speyer I., van Riel P.L. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005, 64:1294-1298.
35. Verstappen S.M., Jacobs J.W., van der Veen M.J., Heurkens A.H., Schenk Y., ter Borg E.J., et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007, 66:1443-1449.
36. Visser K., Katchamart W., Loza E., Martinez-Lopez J.A., Salliot C., Trudeau J., et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009, 68:1086-1093.
37. Hoes J.N., Jacobs J.W., Buttgereit F., Bijlsma J.W. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010, 6:693-702.
38. van Vollenhoven R.F., Ernestam S., Geborek P., Petersson I.F., Coster L., Waltbrand E., et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009, 374:459-466.
39. Mitroulis I., Skendros P., Ritis K. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med 2010, 21:157-163.
40. Salliot C., Finckh A., Katchamart W., Lu Y., Sun Y., Bombardier C., et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011, 70:266-271.
41. De Stefano R., Frati E., Nargi F., Baldi C., Menza L., Hammoud M., et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol 2010, 29:517-524.
42. Finckh A., Dehler S., Gabay C. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis 2009, 68:33-39.
43. Feldmann M., Maini R.N. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?. J Immunol 2010, 185:791-794.
44. Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biologics 2009, 3:183-191.
45. Martin-Mola E., Balsa A. Infectious complications of biologic agents. Rheum Dis Clin North Am 2009, 35:183-199.
46. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., Montero D., Pascual-Gomez E., Mola E.M., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005, 52:1766-1772.
47. Zhou H., Jang H., Fleischmann R.M., Bouman-Thio E., Xu Z., Marini J.C., et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007, 47:383-396.
48. Fleischmann R. The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis. Expert Opin Biol Ther 2010, 10:773-786.
49. Emery P., Fleischmann R.M., Moreland L.W., Hsia E.C., Strusberg I., Durez P., et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009, 60:2272-2283.
50. Keystone E., Genovese M.C., Klareskog L., Hsia E.C., Hall S., Miranda P.C., et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010, 69:1129-1135.
51. Kremer J., Ritchlin C., Mendelsohn A., Baker D., Kim L., Xu Z., et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010, 62:917-928.
52. Smolen J.S., Kay J., Doyle M.K., Landewe R., Matteson E.L., Wollenhaupt J., et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009, 374:210-221.
53. Fleischmann R., Vencovsky J., van Vollenhoven R.F., Borenstein D., Box J., Coteur G., et al. Efficacy and safety of certolizumab pegol monotherapy every 4weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009, 68:805-811.
54. Keystone E., Heijde D., Mason D., Landewe R., Vollenhoven R.V., Combe B., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008, 58:3319-3329.
55. Smolen J., Landewe R.B., Mease P., Brzezicki J., Mason D., Luijtens K., et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009, 68:797-804.
56. Singh J.A., Christensen R., Wells G.A., Suarez-Almazor M.E., Buchbinder R., Lopez-Olivo M.A., et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009, CD007848.
57. Karlsson J.A., Kristensen L.E., Kapetanovic M.C., Gulfe A., Saxne T., Geborek P. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008, 47:507-513.
58. Remy A., Avouac J., Gossec L., Combe B. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol 2011, 29:96-103.
59. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
60. Weinblatt M., Combe B., Covucci A., Aranda R., Becker J.C., Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006, 54:2807-2816.
61. Genovese M.C., Schiff M., Luggen M., Becker J.C., Aranda R., Teng J., et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008, 67:547-554.
62. Emery P., Keystone E., Tony H.P., Cantagrel A., van Vollenhoven R., Sanchez A., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008, 67:1516-1523.
63. Finckh A., Ciurea A., Brulhart L., Kyburz D., Moller B., Dehler S., et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007, 56:1417-1423.
64. Finckh A., Ciurea A., Brulhart L., Moller B., Walker U.A., Courvoisier D., et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?. Ann Rheum Dis 2010, 69:387-393.
65. Jacobi A.M., Dorner T. Current aspects of anti-CD20 therapy in rheumatoid arthritis. Curr Opin Pharmacol 2010, 10:316-321.
66. Emery P., Deodhar A., Rigby W.F., Isaacs J.D., Combe B., Racewicz A.J., et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010, 69:1629-1635.
67. Rubbert-Roth A., Tak P.P., Zerbini C., Tremblay J.L., Carreno L., Armstrong G., et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) 2010.
68. http://clinicaltrials.gov/ct2/show/NCT01309282?term=portsmab&rank=1.
69. Kremer J.M., Blanco R., Brzosko M., Burgos-Vargas R., Halland A.M., Vernon E., et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011, 63:609-621.
70. Platt A.M., Gibson V.B., Patakas A., Benson R.A., Nadler S.G., Brewer J.M., et al. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol 2010.
71. Emery P., Durez P., Dougados M., Legerton C.W., Becker J.C., Vratsanos G., et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010, 69:510-516.
72. Emery P., Breedveld F.C., Hall S., Durez P., Chang D.J., Robertson D., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372:375-382.
73. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37.
74. Smolen J.S., Van Der Heijde D.M., St Clair E.W., Emery P., Bathon J.M., Keystone E., et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006, 54:702-710.
75. van der Kooij S.M., le Cessie S., Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., van Zeben D., Kerstens P.J., et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2009, 68:1153-1158.
76. Soubrier M., Puechal X., Sibilia J., Mariette X., Meyer O., Combe B., et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 2009, 48:1429-1434.
77. Jones G., Sebba A., Gu J., Lowenstein M.B., Calvo A., Gomez-Reino J.J., et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010, 69:88-96.
78. Westhovens R., Robles M., Ximenes A.C., Nayiager S., Wollenhaupt J., Durez P., et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009, 68:1870-1877.
79. Tak P.P., Rigby W.F., Rubbert-Roth A., Peterfy C.G., van Vollenhoven R.F., Stohl W., et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011, 70:39-46.
80. van Vollenhoven R.F. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009, 5:531-541.
81. Alivernini S., Laria A., Gremese E., Zoli A., Ferraccioli G. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Res Ther 2009, 11:R163.
82. http://clinicaltrials.gov/ct2/show/NCT00966875?term=IL+17&rank=11.
83. Genovese M.C., Van den Bosch F., Roberson S.A., Bojin S., Biagini I.M., Ryan P., et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010, 62:929-939.
84. http://clinicaltrials.gov/ct2/show/NCT00718718?term=IL6+antibody+arthritis&rank=3.
85. Cornish A.L., Campbell I.K., McKenzie B.S., Chatfield S., Wicks I.P. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009, 5:554-559.
86. http://clinicaltrials.gov/ct2/show/NCT01023256?term=GM+CSF+arthritis&rank=1.
87. http://clinicaltrials.gov/ct2/show/NCT00995449?term=GM+CSF+arthritis&rank=2.
88. http://clinicaltrials.gov/ct2/show/NCT01050998?term=GM+CSF+arthritis&rank=3.
89. Kausar F., Mustafa K., Sweis G., Sawaqed R., Alawneh K., Salloum R., et al. Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther 2009, 9:889-895.
90. Milani C., Castillo J. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther 2009, 11:200-207.
91. Ostergaard M., Baslund B., Rigby W., Rojkovich B., Jorgensen C., Dawes P.T., et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 2010, 62:2227-2238.
92. Riese R.J., Krishnaswami S., Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010, 24:513-526.
93. Boers M. Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations. Arthritis Rheum 2011, 63:329-330.
94. Deodhar A., Dore R.K., Mandel D., Schechtman J., Shergy W., Trapp R., et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2010, 62:569-574.
95. Tyndall A., van Laar J.M. Stem cells in the treatment of inflammatory arthritis. Best Pract Res Clin Rheumatol 2010, 24:565-574.
96. Farge D., Labopin M., Tyndall A., Fassas A., Mancardi G.L., Van Laar J., et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010, 95:284-292.
97. Bouffi C., Djouad F., Mathieu M., Noel D., Jorgensen C. Multipotent mesenchymal stromal cells and rheumatoid arthritis: risk or benefit?. Rheumatology (Oxford) 2009, 48:1185-1189.